Home
JANX
JANX News

Latest Janux Therapeutics Inc. (JANX) News on April 4, 2025

Is Janux Therapeutics Inc. (NASDAQ:JANX) the Best Up and Coming Stock to Buy According to Wall Street Analysts?

Insider Monkey

7 days ago

Is Janux Therapeutics Inc. (NASDAQ:JANX) the Best Up and Coming Stock to Buy According to Wall Street Analysts?

Is Janux Therapeutics, Inc. (NASDAQ:JANX) the Best Small Cap Stock to Buy Before They Explode?

Insider Monkey

8 days ago

Is Janux Therapeutics, Inc. (NASDAQ:JANX) the Best Small Cap Stock to Buy Before They Explode?

Janux Therapeutics, Inc. (JANX): Among Stocks Receiving the Most Insider Love in March

Insider Monkey

10 days ago

Janux Therapeutics, Inc. (JANX): Among Stocks Receiving the Most Insider Love in March

We're Interested To See How Janux Therapeutics (NASDAQ:JANX) Uses Its Cash Hoard To Grow

Simply Wall St.

10 days ago

We're Interested To See How Janux Therapeutics (NASDAQ:JANX) Uses Its Cash Hoard To Grow

Is Janux Therapeutics (JANX) a Worst High-Risk High-Reward Growth Stock to Buy?

Insider Monkey

15 days ago

Is Janux Therapeutics (JANX) a Worst High-Risk High-Reward Growth Stock to Buy?

WEX, Lamb Weston, and More Stocks See Action From Activist Investors

Barrons.com

21 days ago

WEX, Lamb Weston, and More Stocks See Action From Activist Investors

Biotech Alert: Searches spiking for these stocks today

TipRanks

21 days ago

Biotech Alert: Searches spiking for these stocks today

Janux Therapeutics, Inc. (JANX): Among The Stocks With At Least $30 Million In Insider Spending Recently

Insider Monkey

a month ago

Janux Therapeutics, Inc. (JANX): Among The Stocks With At Least $30 Million In Insider Spending Recently

Janux Therapeutics price target lowered to $41 from $62 at Scotiabank

TipRanks

a month ago

Janux Therapeutics price target lowered to $41 from $62 at Scotiabank

MT Newswires

a month ago

Wedbush Adjusts Price Target on Janux Therapeutics to $76 From $75, Maintains Outperform Rating

Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Business Wire

a month ago

Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Janux Therapeutics, Inc. (JANX): Among the Oversold Biotech Stocks to Buy Now

Insider Monkey

a month ago

Janux Therapeutics, Inc. (JANX): Among the Oversold Biotech Stocks to Buy Now

MT Newswires

2 months ago

Janux Therapeutics Promotes Zachariah McIver to Chief Medical Officer

Business Wire

2 months ago

Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

Business Wire

4 months ago

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

MT Newswires

4 months ago

Janux Therapeutics Prices $350 Million Offering of Shares, Warrants

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Business Wire

4 months ago

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Why Janux Therapeutics Crushed the Market Today

Motley Fool

4 months ago

Why Janux Therapeutics Crushed the Market Today

JANX Stock Hits Record High on Prostate Cancer Study Data

Zacks

4 months ago

JANX Stock Hits Record High on Prostate Cancer Study Data

MT Newswires

4 months ago

Janux Therapeutics Launches $300 Million Offering

Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride

Investor's Business Daily

4 months ago

Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride

Janux Therapeutics Announces Proposed Public Offering

Business Wire

4 months ago

Janux Therapeutics Announces Proposed Public Offering

MT Newswires

4 months ago

Sector Update: Health Care Stocks Mixed Late Afternoon

MT Newswires

4 months ago

Sector Update: Health Care Stocks Higher Tuesday Afternoon

MT Newswires

4 months ago

Sector Update: Health Care

MT Newswires

4 months ago

Janux Therapeutics Shares Soar After Reporting 'Positive' Interim Data for JANX007 in Prostate Cancer Patients

Janux Rockets 41% in Five Days as Cancer Breakthrough Fuels Market Buzz

GuruFocus.com

4 months ago

Janux Rockets 41% in Five Days as Cancer Breakthrough Fuels Market Buzz

Janux Therapeutics Stock Soars on Prostate Cancer Drug Trial Results

Barrons.com

4 months ago

Janux Therapeutics Stock Soars on Prostate Cancer Drug Trial Results

GuruFocus.com

4 months ago

Janux Skyrockets: 69% Surge This Morning Leads to 650% Gain in a Year

Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients

Investor's Business Daily

4 months ago

Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients

MT Newswires

4 months ago

Scotiabank Raises Price Target on Janux Therapeutics to $62 From $42, Keeps Sector Perform Rating

MT Newswires

4 months ago

Top Premarket Gainers

Business Wire

4 months ago

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

MT Newswires

4 months ago

Janux Therapeutics Insider Sold Shares Worth $1,289,879, According to a Recent SEC Filing

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies

Business Wire

4 months ago

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies

Janux Therapeutics initiated with an Outperform at Leerink

TipRanks

4 months ago

Janux Therapeutics initiated with an Outperform at Leerink

MT Newswires

4 months ago

Leerink Initiates Janux Therapeutics at Outperform With $79 Price Target

Bitdeer Technologies, PBF Energy, and More Stocks See Action From Activist Investors

Barrons.com

5 months ago

Bitdeer Technologies, PBF Energy, and More Stocks See Action From Activist Investors

Janux Therapeutics Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.

5 months ago

Janux Therapeutics Third Quarter 2024 Earnings: Misses Expectations

MT Newswires

5 months ago

Wedbush Adjusts Janux Therapeutics Price Target to $75 From $74, Maintains Outperform Rating

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Business Wire

5 months ago

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Bath & Body Works, Paramount Global, and More Stocks See Action From Activist Investors

Barrons.com

5 months ago

Bath & Body Works, Paramount Global, and More Stocks See Action From Activist Investors

MT Newswires

5 months ago

UBS Initiates Janux Therapeutics With Buy Rating, $69 Price Target

Paradigm Biocapital Advisors LP Acquires Shares in Janux Therapeutics Inc

GuruFocus.com

5 months ago

Paradigm Biocapital Advisors LP Acquires Shares in Janux Therapeutics Inc

RA Capital Management Reduces Stake in Janux Therapeutics

GuruFocus.com

5 months ago

RA Capital Management Reduces Stake in Janux Therapeutics

Argus Research

5 months ago

Daily – Vickers Top Buyers & Sellers for 10/21/2024

Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Simply Wall St.

6 months ago

Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Janux Therapeutics, Inc. (JANX): A Hot Stock to Buy Now

Insider Monkey

6 months ago

Janux Therapeutics, Inc. (JANX): A Hot Stock to Buy Now

Argus Research

6 months ago

Daily – Vickers Top Buyers & Sellers for 10/01/2024

MT Newswires

6 months ago

Janux Therapeutics Insider Sold Shares Worth $2,297,755, According to a Recent SEC Filing

MT Newswires

6 months ago

Janux Therapeutics Insider Sold Shares Worth $1,157,641, According to a Recent SEC Filing

Is Janux Therapeutics Inc. (JANX) the Best Performing Small-Cap Stock in 2024?

Insider Monkey

6 months ago

Is Janux Therapeutics Inc. (JANX) the Best Performing Small-Cap Stock in 2024?

Lennar, Bitdeer, and More Stocks See Action From Activist Investors

Barrons.com

6 months ago

Lennar, Bitdeer, and More Stocks See Action From Activist Investors

GuruFocus.com

7 months ago

RA Capital Management L.P. Increases Stake in Janux Therapeutics Inc

Janux Therapeutics, Inc. (JANX): Among Hedge Funds’ Top Biotech Stock Picks

Insider Monkey

7 months ago

Janux Therapeutics, Inc. (JANX): Among Hedge Funds’ Top Biotech Stock Picks

Argus Research

7 months ago

Daily – Vickers Top Buyers & Sellers for 09/13/2024

Janux Therapeutics (JANX) Moves 6.5% Higher: Will This Strength Last?

Zacks

7 months ago

Janux Therapeutics (JANX) Moves 6.5% Higher: Will This Strength Last?

Argus Research

7 months ago

Daily – Vickers Top Buyers & Sellers for 09/11/2024

MT Newswires

7 months ago

Stifel Nicolaus Initiates Coverage on Janux Therapeutics With Buy Rating, $70 Price Target

Southwest Airlines, Rocket Lab USA, and More Stocks See Action From Activist Investors

Barrons.com

8 months ago

Southwest Airlines, Rocket Lab USA, and More Stocks See Action From Activist Investors

Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Tops Revenue Estimates

Zacks

8 months ago

Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Tops Revenue Estimates

Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Business Wire

8 months ago

Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Janux Therapeutics Announces Updates to Board of Directors

Business Wire

8 months ago

Janux Therapeutics Announces Updates to Board of Directors

TruBridge, Evans Bancorp, and More Stocks See Action From Activist Investors

Barrons.com

10 months ago

TruBridge, Evans Bancorp, and More Stocks See Action From Activist Investors

Lotto 6/49 - $64 million up for grabs in the next draw!

CNW Group

10 months ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Simply Wall St.

10 months ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North

AFP

10 months ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

Simply Wall St.

10 months ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Simply Wall St.

10 months ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Barrons.com

10 months ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

Simply Wall St.

10 months ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Simply Wall St.

10 months ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Argus Research

10 months ago

Daily – Vickers Top Buyers & Sellers for 06/06/2024

MT Newswires

10 months ago

Janux Therapeutics Insider Sold Shares Worth $45,043,975, According to a Recent SEC Filing

MT Newswires

10 months ago

Janux Therapeutics Insider Sold Shares Worth $82,125,000, According to a Recent SEC Filing

MT Newswires

10 months ago

Scotiabank Starts Janux Therapeutics With Sector Perform Rating

We're Not Very Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Rate

Simply Wall St.

a year ago

We're Not Very Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Rate

MT Newswires

a year ago

Wedbush Raises Janux Therapeutics' PT to $74 From $53, Keeps Outperform Rating

Janux Therapeutics Reports Narrower Q1 Loss, Misses Revenue Estimates

GuruFocus.com

a year ago

Janux Therapeutics Reports Narrower Q1 Loss, Misses Revenue Estimates

Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Business Wire

a year ago

Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Here's What Could Help Janux Therapeutics (JANX) Maintain Its Recent Price Strength

Zacks

a year ago

Here's What Could Help Janux Therapeutics (JANX) Maintain Its Recent Price Strength

Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors

Zacks

a year ago

Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors

Janux Therapeutics (JANX) is on the Move, Here's Why the Trend Could be Sustainable

Zacks

a year ago

Janux Therapeutics (JANX) is on the Move, Here's Why the Trend Could be Sustainable

Why Janux Therapeutics Stock Is Crushing It This Week

Motley Fool

a year ago

Why Janux Therapeutics Stock Is Crushing It This Week

Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday?

Benzinga

a year ago

Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday?

Wall Street Analysts Think Janux Therapeutics (JANX) Could Surge 40.3%: Read This Before Placing a Bet

Zacks

a year ago

Wall Street Analysts Think Janux Therapeutics (JANX) Could Surge 40.3%: Read This Before Placing a Bet

Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options

Investor's Business Daily

a year ago

Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options

Why Janux Therapeutics Stock Soared as the Market Sagged Today

Motley Fool

a year ago

Why Janux Therapeutics Stock Soared as the Market Sagged Today

After Plunging -11.78% in 4 Weeks, Here's Why the Trend Might Reverse for Janux Therapeutics (JANX)

Zacks

a year ago

After Plunging -11.78% in 4 Weeks, Here's Why the Trend Might Reverse for Janux Therapeutics (JANX)

Janux Therapeutics (JANX) Upgraded to Buy: Here's What You Should Know

Zacks

a year ago

Janux Therapeutics (JANX) Upgraded to Buy: Here's What You Should Know

Wall Street Analysts Believe Janux Therapeutics (JANX) Could Rally 57.47%: Here's is How to Trade

Zacks

a year ago

Wall Street Analysts Believe Janux Therapeutics (JANX) Could Rally 57.47%: Here's is How to Trade

Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst

Benzinga

a year ago

Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst

2 Stocks That Have More Than Tripled This Year: Are They Buys?

Motley Fool

a year ago

2 Stocks That Have More Than Tripled This Year: Are They Buys?

GuruFocus.com

a year ago

Janux Therapeutics Inc (JANX) Reports Encouraging Clinical Data and Solid Financial Position ...

Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Business Wire

a year ago

Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

The Zacks Analyst Blog Highlights Janux Therapeutics, SoundHound, Root, Equillium and CleanSpark

Zacks

a year ago

The Zacks Analyst Blog Highlights Janux Therapeutics, SoundHound, Root, Equillium and CleanSpark

After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy?

Motley Fool

a year ago

After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy?

5 Stocks That More Than Doubled in February

Zacks

a year ago

5 Stocks That More Than Doubled in February

Recent Price Trend in Janux Therapeutics, Inc. (JANX) is Your Friend, Here's Why

Zacks

a year ago

Recent Price Trend in Janux Therapeutics, Inc. (JANX) is Your Friend, Here's Why

Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Business Wire

a year ago

Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Share on Social Networks: